Merck Pausing Enrollment for Two Trials of Oral Islatravir

By Stephen Nakrosis


Merck & Co. said Monday it would pause enrollment in Phase 3 clinical studies evaluating oral islatravir for pre-exposure prophylaxis in people at high risk of HIV-1... | December 7, 2021

Related Keywords

Stephen Nakrosis ,Merck Co ,Dow Jones ,Nc Stock Exchange ,News ,Information ,Press Release ,Y ,Stephen ,Nakrosis ,Merck ,Aid ,Monday ,It ,Would ,Cause ,Enrollment ,N ,Hase , ,Linical ,Studies ,Valuating ,Mural ,Islatravir ,Or ,Prophylaxis ,People ,Thigh ,Risk ,F Mrk Us58933y1055 ,